Therefore, to evaluate the association of tumor HPV16 status with combined risk genotypes of both polymorphisms, the study subjects were categorized into three main groups based on the level of association of tumor HPV16 positivity with variant genotypes of each polymorphism (Table 3): 1) the low-risk group (if subjects with p53 Arg/Arg and p73 GC/GC genotypes); 2) the medium-risk group (if subjects with p53 Arg/Arg and p73 AT carriers or p53 Pro carriers and p73 GC/GC genotypes); and 3) the high-risk group (if subjects with p53 Pro carriers and p73 AT carriers), respectively. This evidence concerns the gene TP53 and neoplasm.